AbbVie
ABBV
#28
Rank
NZ$788.81 B
Marketcap
NZ$446.47
Share price
-2.42%
Change (1 day)
44.19%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2026 (TTM): NZ$3.51

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$3.60. In 2025 the company made an earnings per share (EPS) of NZ$4.19 a decrease over its 2024 EPS that were of NZ$4.24.

EPS history for AbbVie from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$3.51-16.27%
2025NZ$4.19-1.26%
2024NZ$4.24-11.86%
2023NZ$4.82-58.95%
2022NZ$11.732.49%
2021NZ$11.45121.58%
2020NZ$5.17-44.7%
2019NZ$9.3445.84%
2018NZ$6.419.72%
2017NZ$5.84-9.54%
2016NZ$6.4516.28%
2015NZ$5.55184.1%
2014NZ$1.95-57.15%
2013NZ$4.56

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.30-36.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$49.46 1,272.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$25.38 604.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$16.39 354.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$12.00 233.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.24 73.12%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$12.18 237.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$6.81 88.99%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$11.76 226.30%๐Ÿ‡บ๐Ÿ‡ธ USA